DEWANA BOBO: Open Payments
NPI 1679612634 · ST. FRANCISVILLE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$894 in 54 payments from 12 companies in 2025. Trend: 2023 $729 · 2024 $890 · 2025 $894
Food & beverage: $894
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 20 | $170 |
| Axsome Therapeutics, Inc. | 3 | $150 |
| GlaxoSmithKline, LLC. | 8 | $145 |
| PFIZER INC. | 6 | $104 |
| Novo Nordisk Inc | 5 | $91 |
| Lilly USA, LLC | 2 | $44 |
| Boston Scientific Corporation | 2 | $43 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $42 |
| Dexcom, Inc. | 2 | $41 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $25 |
Products named: VRAYLAR, Auvelity, TRELEGY ELLIPTA, ELIQUIS, Wegovy, Kerendia, Dexcom G6 Transmitter, ZEPBOUND.
Industry payments across LA — which companies pay providers there.
